Skip to main content

Participation in a Heart Failure Clinical Trial: Perspectives and Opportunities From the VICTORIA Trial and VICTORIA Simultaneous Registry.

Publication ,  Journal Article
Ezekowitz, J; Mentz, RJ; Westerhout, CM; Sweitzer, NK; Givertz, MM; Piña, IL; O'Connor, CM; Greene, SJ; McMullan, C; Roessig, L; Hernandez, AF ...
Published in: Circ Heart Fail
September 2021

BACKGROUND: Randomized controlled trials (RCTs) often target enrollment of patients with demographics and outcomes less representative of the broader population of interest. To provide context for the VICTORIA trial (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction), we designed a registry of hospitalized patients with worsening heart failure to characterize their clinical profile, outcomes, and reasons for their nonparticipation in a RCT. METHODS: Fifty-one RCT sites in Canada and the United States participated. Eligible patients included those with chronic heart failure, hospitalized for heart failure, and an ejection fraction <45%; no other exclusions were applied. Sites identified patients between 2017 and 2019 during the RCT enrollment period. RCT eligibility criteria were applied, and non-mutually exclusive reasons for nonenrollment were captured. Mortality at 1 year was estimated via the Meta-Analysis Global Group in Chronic Heart Failure risk score or as observed in the RCT. RESULTS: Overall, 2056 patients were enrolled in the registry; 61% (n=1256) were ineligible for the RCT, 37% (n=766) were eligible but not enrolled, and 2% (n=34) were also enrolled in the RCT. Registry participants had a median age of 70, 33% were women, and 63% were White. The median risk score predicted a 20.9% 1-year mortality, higher than in the RCT (predicted 14.7% and observed 11.5%). Major reasons for ineligibility in the RCT included the use of nitrates (23%), systolic blood pressure <100 mm Hg (12%), and substance use (11%) with other exclusion criteria <10%. For eligible patients, reasons for nonparticipation in the RCT included lack of interest in participating (28%), poor compliance (25%), inability to complete follow-up (23%), too sick (20%), unable to provide consent (17%), and distance from site (15%). CONCLUSIONS: Patients with worsening heart failure in routine clinical practice exhibit high-risk features, and approximately one-third were eligible for an RCT but excluded. The majority of these nonparticipating patients had modifiable reasons. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02861534.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Circ Heart Fail

DOI

EISSN

1941-3297

Publication Date

September 2021

Volume

14

Issue

9

Start / End Page

e008242

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Stroke Volume
  • Registries
  • Middle Aged
  • Male
  • Humans
  • Hospitalization
  • Heart Failure
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ezekowitz, J., Mentz, R. J., Westerhout, C. M., Sweitzer, N. K., Givertz, M. M., Piña, I. L., … Armstrong, P. W. (2021). Participation in a Heart Failure Clinical Trial: Perspectives and Opportunities From the VICTORIA Trial and VICTORIA Simultaneous Registry. Circ Heart Fail, 14(9), e008242. https://doi.org/10.1161/CIRCHEARTFAILURE.120.008242
Ezekowitz, Justin, Robert J. Mentz, Cynthia M. Westerhout, Nancy K. Sweitzer, Michael M. Givertz, Ileana L. Piña, Christopher M. O’Connor, et al. “Participation in a Heart Failure Clinical Trial: Perspectives and Opportunities From the VICTORIA Trial and VICTORIA Simultaneous Registry.Circ Heart Fail 14, no. 9 (September 2021): e008242. https://doi.org/10.1161/CIRCHEARTFAILURE.120.008242.
Ezekowitz J, Mentz RJ, Westerhout CM, Sweitzer NK, Givertz MM, Piña IL, et al. Participation in a Heart Failure Clinical Trial: Perspectives and Opportunities From the VICTORIA Trial and VICTORIA Simultaneous Registry. Circ Heart Fail. 2021 Sep;14(9):e008242.
Ezekowitz, Justin, et al. “Participation in a Heart Failure Clinical Trial: Perspectives and Opportunities From the VICTORIA Trial and VICTORIA Simultaneous Registry.Circ Heart Fail, vol. 14, no. 9, Sept. 2021, p. e008242. Pubmed, doi:10.1161/CIRCHEARTFAILURE.120.008242.
Ezekowitz J, Mentz RJ, Westerhout CM, Sweitzer NK, Givertz MM, Piña IL, O’Connor CM, Greene SJ, McMullan C, Roessig L, Hernandez AF, Armstrong PW. Participation in a Heart Failure Clinical Trial: Perspectives and Opportunities From the VICTORIA Trial and VICTORIA Simultaneous Registry. Circ Heart Fail. 2021 Sep;14(9):e008242.

Published In

Circ Heart Fail

DOI

EISSN

1941-3297

Publication Date

September 2021

Volume

14

Issue

9

Start / End Page

e008242

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Stroke Volume
  • Registries
  • Middle Aged
  • Male
  • Humans
  • Hospitalization
  • Heart Failure
  • Female